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Hepatitis B vaccination and interleukin-2 receptor expression in
chronic renal failure. Only 50 to 60% of dialysis patients develop
anti-HBs antibodies following hepatitis B vaccination. The nonre-
sponder state correlates with impaired monocyte function, decreased
interleukin-2 (lL-2) production of T cells, and an upregulation of the
IL-2 receptor system. In the present study we examined anti-HBs
production after hepatitis B vaccination and the in vitro expression of
lL-2 receptors in nondialyzed patients with various degrees of chronic
renal failure. Forty-four patients with impaired renal function were
immunized with 20 sg recombinant hepatitis B vaccine and boostered
after one and six months. Prior to the first injection IL-2 receptor
expression of activated T cells was studied by an in vitro proliferation
assay. Sixty-four healthy subjects served as controls. After completion
of the third vaccination 55.0% of the patients acquired antibody titers>
10 U/liter. The seroconversion rate did not differ between patients with
lower (< 3.5 mg/dI) and higher (> 3.5 mg/dl) creatinine levels. In
nonresponders IL-2 receptor expression (stimulation index, SI = 10.09
1.80) was elevated compared to healthy controls (SI = 4.62 0.35,
P < 0.002) or patients who responded with a high antibody titer (> 50
U/liter, SI = 3.12 0.43, P < 0.001). Patients who produced low
antibody titers (< 50 U/liter) also presented with enhanced IL-2
receptor expression. These data show that an impaired antibody
production following hepatitis B vaccination and an enhanced lL-2
receptor expression of T cells may already be present in early stages of
chronic renal failure.
In patients with chronic renal failure the antibody production
following active immunization with T cell dependent antigens
may be impaired [1—7]. After hepatitis B vaccination only 50 to
60% of dialysis patients are able to produce protective antibody
titers, which contrasts to the good response rate in healthy
individuals of more than 95% [I—SI. Whereas in healthy nonre-
sponders a genetic defect of antigen presentation may play a
pathogenic role, in dialysis patients an acquired defect in
cellular immune response could be demonstrated by different
authors. In previous investigations we demonstrated that pe-
ripheral blood lymphocytes of dialysis patients show impaired
lgG production after polyclonal stimulation with lectins. More-
over, T cells from those dialysis patients who did not respond to
hepatitis B vaccination responded with a decreased prolifera-
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tion rate to antigen receptor stimulation by monoclonal anti-
bodies [8]. In these patients the production of the T cell growth
factor IL-2 was impaired [8—101. Adequate IL-2 production of I
cells depends on monocyte derived signals [II]. In dialysis
patients a metabolic monocyte defect seems to be responsible
for the decreased IL-2 production, since normal I cell prolifer-
ation is observed when T cells from nonresponders are stimu-
lated in presence of monocytes from healthy donors [12]. In
these patients the decreased IL-2 production is associated with
upregulation of IL-2 receptor expression, which results in an
enhanced sensitivity to exogenous IL-2. In the presence of low
doses of IL-2, T cells from vaccine nonresponders reveal a
markedly enhanced proliferative response following antigen
receptor stimulation when compared with healthy controls [12,
13].
In the preuremic stage of chronic renal failure, that is, in
nondialyzed patients, responder rates following hepatitis B
vaccination are comparable to those of dialysis patients, vary-
ing between 50 and 60% [14—16]. In the present study we
prospectively investigated immune responsiveness following
hepatitis B vaccination and IL-2 receptor expression in patients
with renal insufficiency, particularly with regard to the early
stages of renal disease.
Methods
Patients
Forty-four patients with various degrees of renal function
(serum creatinine. Sçr 1.5 to 16.2 mg/dl) were investigated.
Their ages ranged from 27 to 75 years (mean SD, 51.5 14.5).
The underlying kidney diseases were glomerulonephritis (18
patients), vascular renal disease (7 patients). polycystic kidney
disease (6 patients), interstitial nephritis (7 patients), diabetic
nephropathy (4 patients), light chain deposition disease (I
patient) and Alports syndrome (I patient). All patients were
negative for HBs antigen, anti-HBs and anti-HBc as determined
by routine testing (Auszyme and Ausab by Abbott Laborato-
ries, North Chicago, Illinois, USA). Patients included in this
trial did not receive immunosuppressive treatments or blood
transfusions. Blood samples for in vitro studies were collected
prior to the first vaccination. Sixty-four healthy persons (age 25
to 46 years) served as normal controls.
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After the in vitro studies were performed, patients were
vaccinated by intramuscular application of 20 g recombinant
hepatitis B vaccine (Merck, Sharp und Dohme GmbH, Darm-
stadt, FRG); booster injections were performed after four
weeks and six months. Antibody production was measured by
an ELISA routine test kit (Ausab, Abbott Laboratories) before
the first injection and after four weeks, eight weeks, 24 weeks,
28 weeks and 32 weeks. Patients were regarded as responders if
antibody titers after vaccination were greater than 10 U/liter on
two determinations. All other patients were regarded as nonre-
sponders.
Lymphocyte populations
Twenty milliliters of heparinized blood were drawn before
the first vaccination. Peripheral blood mononuclear cells
(PBMC) were obtained by density gradient centrifugation at 400
x g using a Ficoll-Paque gradient (Pharmacia, Uppsala, Swe-
den). PBMC were recovered from the interface and washed
twice in RPMI 1640 (Gibco), containing 2% human AB serum.
Purified T cells and monocytes
Purified T cells were isolated from PBMC by E-rosetting with
sheep red blood cells. Subsequently, E cells were plated onto
glass petri dishes and incubated overnight at 37°C, 6% C02, in
humified atmosphere in culture medium RPMI 1640 supple-
mented with 10% human AB serum, 1% penicillin-streptomycin
and 2% glutamine (Gibco). Depletion of monocytes was
achieved by incubating of non-adherent E cells with monoclo-
nal antibodies anti-12 and anti-Mo2 in a final dilution of 1:200
(ascites in medium) for 30 minutes at 37°C [12]. It was then
washed once and subsequently treated with preabsorbed rabbit
serum as a source of complement for 60 minutes at 37°C in a
shaking water bath. After three washes cells were adjusted to 2
x 106 cells/ml, incubated overnight in standard culture medium,
and employed as a source of purified resting T lymphocytes.
Interleukin-2 and monoclonal antibodies
Monoclonal antibody CD3 (OKT3) was purchased from Cilag
(Alsbach Hähnlein, FRG). Three milligrams of the antibody
were coupled to 1 ml of swollen CnBr-activated Sepharose
beads (Pharmacia) according to the protocol provided by the
manufacturer. Interleukin-2 was purchased from Biotest AG
(Frankfurt, FRG).
Proliferative assays
A total of 5 x l0 cells were incubated in the presence or
absence of IL-2 (4 U/mI) in round-bottomed microtiter wells
(Costar, USA) in 200 .d of RPMI 1640 supplemented with 10%
human AB serum, 1% penicillin-streptomycin and 2% glu-
tamine. On day 0 cells were stimulated with sepharose linked
anti-CD3. Prior to the tests IL-2 and sepharose coupled anti-
CD3 antibody had been titrated on T cells from three normal
individuals. For the tests a concentration of IL-2 and anti-CD3
sepharose was chosen which resulted in approximately one-
third of the maximum proliferation rate in healthy individuals,
The test was done in triplicate cultures. After three days of
culture, wells were pulsed with 1 pCi of 3H-thymidine for 16
hours and harvested with a Titertek cell harvester (Flow,
Meckenheim, FRG). 3H-thymidine incorporation was measured
Table 1. Seroconversión rate following three vaccinations with 20 &g
hepatitis B vaccine in 44 patients with various degrees of renal
insufficiency
Seroconversion
ratePatients
Group 1 (N = 15) 9/15 (60.00%)
creatinine 1.5—3.5 mg/dl
Group 2 (N = 29) 16/29 (55.17%)
creatinine 3.6—16.2 mg/dl
in a Packard liquid scintillation spectrometer (Packard Instru-
ments C. Inc., Downers Grove, USA).
Results were expressed as a stimulation index:
IL-2 receptor index =
cpm 3H-Thy (anti-CD3 + IL-2)
cpm 3H-Thy (IL-2)
Statistical evaluation
Results are expressed as stimulation index SEM. Signifi-
cance was assessed using two-tailed Wilcoxon rank test for
independent values.
Results
Antibody production
Twenty-five out of 44 patients (56.8%) produced anti-HBs
antibody concentrations of more than 10 U/liter one month after
the third vaccination on two determinations, whereas 19 pa-
tients (43.2%) showed no seroconversion. The proportion of
responders was 60.0% in 15 patients with serum creatinine
below 3.5 mg/dl and 55.17% in 29 patients with serum creatinine
of more than 3.6 mg/dl (Table 1). In the patient group with low
serum creatinine the mean creatinine was 2.5 0.8 (range 1.5 to
3.5 mgldl); in the patient group with high serum creatinine it was
7.0 3.0 (range 3.6 to 16.2 mg/dl). There was no significant
correlation between serum creatinine and response rate (Fig. 1).
IL-2 receptor expression
The 19 nonresponders to hepatitis B vaccination showed an
increase in the IL-2 receptor expression, demonstrated by an
elevated stimulation index of 10.09 1.79 compared to a
stimulation index of 4.62 0.35 in the control group (P <
0.002). Patients with a moderate impairment of renal function
(SCr < 3.5 mgldl) showed this increased IL-2 receptor expres-
sion as well (Fig. 2). There was no difference in IL-2 respon-
siveness between patients with moderate impairment of renal
function (Sr < 3.5 mg/dl) and patients with severe renal
insufficiency (5Cr> 3.5 mg/dl).
Nineteen out of 25 responders produced antibody titers
greater than 50 U/liter. These patients revealed an IL-2 receptor
expression which was comparable to that of the control persons
(stimulation index = 3.12 0.43). In contrast, six low level
responders (10 to 50 U/liter) demonstrated the signs of in-
creased IL-2 receptor expression (stimulation index = 20.07
4.37, Fig. 1). In the case of nonresponders (N = 19) where
anti-HBs titers were < 10 U/liter, 13 (68.0%) were hyperespon-
sive to IL-2 (IL-2 receptor index > 5.0), whereas 5 showed low
IL-2 responsiveness. In contrast, only 2 of 19 good responders
Fig. 1. Prol,ferative responses of 44 patients
with various degrees of renal insufficiency and
64 healthy controls were compared. Patients
with a good response to hepatitis B
vaccination (anti-HBs titers > 50 U/I) show a
low IL.2 receptor index, demonstrating
normal IL-2 receptor expression. Elevated
IL-2 receptor index and non-responsiveness to
hepatitis B vaccination is seen even in
moderate renal insufficiency. Symbols are: (•)
anti-HBs titer > 50 U/liter; (0) anti-HBs titer
10—50 U/liter; () anti-HBs titer < 10 U/liter;
(S) controls SD.
Fig. 2. Patients with anti-HBs titers > 50 U/liter (EJ) after completion
of the vaccination protocol show a normal IL-2 receptor index com-
pared with nonresponders (, anti-HBs < 10 U/liter). There is no
difference between patients with creatinine < 3.5 mg/dI ( = 2.5 0.8)
and patients with creatinine > 3.5 mg/di (x = 7.0 3.1). * <0.05; **
<0.005.
100
anti-HBs titer, U/lifer
FIg. 3. There is a negative correlation between anti-HBs titers and
IL-2 receptorexpression. Patients with a good anti-HBs response show
a low IL-2 receptor index. Symbols are: (0) glomerulonephritis; (•)
vascular renal disease; () polycystic kidney disease; (A) interstitial
nephritis; (0) diabetic nephropathy; (•) others. r = —0.29; P < 0,05.
immunodeficiency [17]. Employing novel in vitro systems to
assess cellular immune functions, we have recently found that
non-responsiveness to hepatitis B vaccination in hemodialysis
patients is associated with reduced production of IL-2 during in
vitro activation of these patients' T lymphocytes [12]. In
contrast, membrane expression of receptors for IL-2 by antigen
receptor-triggered T cells was markedly enhanced as compared
with healthy donors and vaccine responders on hemodialysis.
Moreover, this functional state resulted from an as yet unclear
defect at the monocyte level. It was concluded that, due to
reduced or even absent IL-2 production, the essential process
of generating activated antigen-specific T cells which, in turn,
are required for efficient B cell help in antibody production
cannot be completed. Perhaps more important, revaccination of
previous nonresponders to hepatitis B vaccine in combination
with exogenous low-dose IL-2 was effective in producing pro-
tective antibody titers in the majority of individuals [18].
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(10.5%) with anti-HBs titers > 50 U/liter revealed an lL-2
receptor index of more than 5.0.
The difference between nonresponders and good responders,
that is, patients who produced antibody titers> 50 U/liter, was
significant in both groups, those with moderate (creatinine <
3.5 mg/dl) or severe (creatinine > 3.5 mg/dl) renal insufficiency.
When individual values for IL-2 receptor expression and anti-
HBs titers were evaluated, there was a significant negative
correlation between anti-HBs titers and IL-2 receptor expres-
sion (Fig. 3).
Discussion
Impaired renal function is associated with reduced cellular
immune responses in vivo and in vitro [1—9, 12]. A low rate of
seroconversion in patients on hemodialysis who receive hepa-
titis B vaccines and a high risk of developing chronic hepatitis
B infection represent interrelated consequences of this type of
Dumann et a!: HBs and IL-2 expression in CRF 1167
Given the low seroconversion rate to hepatitis B vaccination,
which also exists in non-dialyzed patients [15, 16] and in rather
early stages of renal failure [141, it was necessary to investigate
whether a similar defect of the cellular immune system may be
responsible and/or associated with this phenomenon.
The present data suggest that a similar type of immunodefi-
ciency as previously observed in dialysis patients exists in
patients with early stages of chronic renal failure. Thus, a
correlation between low anti-HBs production and enhanced
IL-2 receptor expression (Figs. 1, 2, 3) is obvious. It should be
noted, however, that this does not apply to all nonresponders
(Fig. 1) as shown before [12]. The numbers of patients investi-
gated so far regarding this parameter is still relatively small.
Therefore, the exact proportion of uremic individuals where an
enhanced interleukin-2 receptor expression with no response to
exogenous antigens is not known at present. Nevertheless, the
available data suggest that such an abnormality is rather fre-
quent and relevant for the majority of cases.
The present data as well as our previous investigations do not
show a correlation between the underlying kidney disease and
antibody production or cellular immune function [3, 12]. How-
ever, it may be assumed that in individual cases, such as
immune vasculitis, immune responses may be altered by the
renal disease.
The exact basis for the observed immune dysfunction is still
elusive. In this regard, imbalances in the metabolism of potent
immunoregulatory molecules such as IL-I, IL-6, and tumor
necrosis factor (TNF) which may render monocytes incapable
to support T cell activation have been reported [19, 20]. Several
imbalances have been observed in patients on hemodialysis and
were thought to be due to dialysis treatment, particularly to the
type of membrane employed [21—23]. However, individual
immune responses to hepatitis B vaccination as well as cellular
immune functions assessed in vitro did not show a correlation
with this parameter [3, 12]. The notion that metabolic condi-
tions in the course of chronic renal failure are responsible for
the existing immunodeficiency is strongly supported by the
present data which demonstrate that non-dialyzed patients
suffer from an analogous defect. Studies which demonstrate the
immunosuppressive effect of uremic serum in dialysis patients
give additional support to this assumption [8, 241. Investigations
aimed at evaluating influences of homogenous preparations of
recombinant mediators on monocyte function are in progress.
Moreover, plasma and/or serum of immunodeficient patients
needs to be examined, particularly since we have recently
observed that it contains activities which modulate monocyte
activity in primary immune responses [24]. Given the present
analysis, it seems unlikely that the strategy to vaccinate against
hepatitis B in early stages of chronic renal failure will improve
on the response rate. Nethertheless, elevated IL-2 receptor
expression in the absence of IL-2 production has been used as
a clinical indication for reconstitution therapy with exogenous
IL-2. Therefore, we suggest that patients with early stages of
renal failure may benefit from a combined application of hepa-
titis B vaccine plus IL-2 for prevention of chronic hepatitis B
infection.
Acknowledgment
We thank Mrs. E. Schiedheim for technical assistance.
Reprint requests to Prof. Dr. H. KOhler, I. Medizinische Klinik der
Johannes Gutenberg Universitdt Mainz, Langenbeckstr. 1, 6500 Mainz,
Federal Republic of Germany.
References
I. CROSNIER J, JUNGERS P, CouRocE AM, LAPLANCHE A, BEN-
HAMOU E, DEGOS F, LACOUR B, PRUNET P. CERISIER Y, GUESRY
P: Randomised placebo controlled trial of hepatitis B surface
antigen vaccine in French hemodialysis units: II. Hemodialysis
patients. Lancet 1:797—800, 1981
2. DESMYTER J, COLAERT J, DE GROOTE G, REYNDERS M, REEIUNG-
BRONGERS EE, DEE5 PJ, LELIE PN, REESINK HW: Efficacy of
heat-inactivated hepatitis B vaccine in hemodialysis patients and
staff. Lancet 11:1323—1327, 1983
3. KOHLER H, ARNOLD W, RENSCHIN 0, DORMEYER HH, MEYER
ZUM BUSCHENFELDE KH: Active hepatitis B vaccination of dialy-
sis patients and medical staff. Kidney mt 25:124—128, 1984
4. STEVENS CE, ALTER HJ, TAYLOR PE, ZANG EA, HARLEY EJ,
SZMUNESS W: Hepatitis B vaccine in patients receiving hemodial-
ysis. NEng!JMed3ll:496—501, 1984
5. KOHLER H, DUMANN H, MEYER ZUM BUSCHENFELDE KH,
MEUER SC: Sekundärer Immundefekt bei Niereninsuffizienz am
Beispiel der Hepatitis B lmpfung. K/in Wochenschr 66:865—872,
1988
6. CAPPEL R, VAN BEERS D, LIESNARD C, DRATWA M: Impaired
humoral and cell-mediated immune responses in dialyzed patients
after influenza vaccination. Nephron 33:21—25, 1983
7. BEYER WEP, VER5LuI5 DJ, KRAMER P, DIDERICH PP. WEIMAR W,
MASUREL N: Trivalent influenza vaccine in patients on hemodial-
ysis: Impaired seroresponse with differences for A-H3N2 and
A-H IN I vaccine components. Vaccine 5:43—48, 1987
8. Kuitz P, KOHLER H, MEUER SC, HOTTEROTH T, MEYER ZUM
BUSCHENFELDE KH: Impaired cellular immune response in chronic
renal failure: Evidence for a T cell defect. Kidney mt 29:1209—1214,
1986
9. CHATENOUD L, DUGAS B, BEAURAIN 0, TOUAM M, DRUEKE 1',
VASQUEZ A, GALANAUD P. BACH iF, DELFRAISSY JF: Presence of
preactivated T cells in hemodialyzed patients: Their possible role in
altered immunity. Proc Nat! Acad Sci USA 83:7457—7461, 1986
10. LANGHOFF E, HOFMANN B, ØDUM N, LADEFOGED J, PLATZ P,
RYDER LP, SVEJGAARD A: Kinetic analysis of interleukin (IL-2)
production and expression of IL-2 receptors by uraemic and normal
lymphocytes. Scand J Immuno! 25:29—36, 1987
II. MEUER SC, MEYER ZUM BUSCHENFELDE KH: T cell receptor
triggering induces responsiveness to interleukin- I and interleukin-2
but does not lead to T cell proliferation. J Immunol 136:4106—4112,
1986
12. MEUER SC, HAUER M, Kuitz P, MEYER ZUM BOSCHENFELDE KH,
KOHLER H: Selective blockade of the antigen-receptor mediated
pathway of T cell activation in patients with impaired primary
immune responses. J C/in Invest 80:743—749, 1987
13. BEAURAIN 0, NARET C, MARCON L, GRATEAU G, DRUEKE T,
URENA P. NELSON DL, BACH iF, CHATENOUD L: In vivo T cell
preactivation in chronic uremic hemodialyzed and non-hemodia-
lyzed patients. Kidney mt 36:636—644, 1989
14. Kuitz P. KOHLER H, HUTTEROTH T, WEBER M, MEYER ZUM
BUSCHENFELDE KH: Immune defect in the early stage of chronic
renal failure. Proc EDTA -ERA 22:941—945, 1985
15. JUNCERS P, CHAUVEAU P. COUROUCE AM, MATTLINGER B,
CROSNIER J: Hepatitis B vaccine in non-dialyzed uraemic patients:
Preliminary results. Proc EDTA-ERA 22:1073—1076, 1985
16. BOMMER J, GRUSSENDORF M, JILG W, DEINHARDT F, KocH HG,
DARAI G, BOMMER 0, RAMBAU5EK M, RITz E: Vaccination against
hepatitis B in patients with renal insufficiency. Proc EDTA-ERA
21:300—305, 1984
17. MEUER SC, KOHLER H, MEYER ZUM BUSCHENFELDE KH: Mono-
cyte defect in hemodialysis patients supports nonresponsiveness to
hepatitis B vaccination and development of HB5Ag carrier state, in
Viral Hepatitis and Liver Disease, edited by ZUCKERMANN Al,
New York, Alan Liss Inc. 1988, pp 711—713
18. MEUER SC, DUMANN H, MEYER ZUM BUSCHENFELDE KH,
KOHLER H: Low dose interleukin-2 induces systemic immune
1168 Dumann et a!: HBs and IL-2 expression in CRF
responses against HBsAg in immunodeficient non-responders to
hepatitis B vaccination. Lance! 1:15—18, 1989
19. J0NsT0N RB: Current concepts—immunology: Monocytes and
macrophages. N Eng! J Med 318:747—752, 1988
20. KIsHIM0T0 T, KIiMo T: Molecular regulation of B lymphocyte
response, in Annual Rev Immuno! (vol 6), edited by PAUL WE, Palo
Alto, Annual Reviews Inc. 1988, pp 485—5 12
21. DINARELLO CA: The biology of interleukin-l and its relevance to
hemodialysis. Blood Purif 1:197—224, 1983
22. BINGEL M, LONNEMANN G, KOCH KM, DINARELLO CA, SHAL-
DON S: Plasma interleukin I activity during hemodialysis: The
influence ofdialysis membranes. Nephron 50:273—276, 1988
23. BLUMENSTEIN M, SCHMIDT B, WARD RA, ZIEGLER-HEITBROCK
HWL, GURLAND HJ: Altered interleukin-1 production in patients
undergoing hemodialysis. Nephron 50:277—281, 1988
24. DUMANN H, MEUER SC, KOHLER H: Uremic serum inhibits
monocyte dependent, but not interleukin-2 dependent steps of T
cell proliferation. Nephron (in press)
